GlassScriptPhysician profile
Thea C Cooper Barton
NPI 1881861920
$4,834.90
in general payments reported to CMS, 2019-2025
26 companies · $567 in 2025
The $567 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $374 · 2021: $1,064 · 2022: $2,002 · 2023: $310 · 2024: $288 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.51 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,149.52 | 2022 | |
| Abbvie INC. | $1,078.70 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Therapeuticsmd, INC. | $529.09 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $273.43 | 2021-2025 | |
| Evofem Biosciences, INC. | $254.28 | 2021-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $240.71 | 2024-2025 | Veozah |
| Avion Pharmaceuticals | $214.27 | 2020-2022 | |
| Exeltis, USA INC. | $193.39 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $131.71 | 2019-2023 | Endosee |
| Millicent US INC | $98.51 | 2020-2025 | Intrarosa, Femlyv |
| Lupin INC. | $86.68 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $74.77 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $70.65 | 2021-2022 | |
| Sage Therapeutics, LLC | $66.19 | 2025 | Zurzuvae |
| Currax Pharmaceuticals LLC | $61.94 | 2025 | Contrave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $50.95 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Allergan, INC. | $50.07 | 2019-2020 | |
| Organon LLC | $44.90 | 2023-2024 | |
| Novo Nordisk INC | $29.64 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $23.05 | 2025 | Ojjaara |
| Becton, Dickinson and Company | $22.00 | 2021 | |
| Myovant Sciences INC. | $21.96 | 2022 | |
| Avanos Medical | $19.61 | 2019 | |
| Pfizer INC. | $16.71 | 2024 | |
| Lilly USA, LLC | $16.55 | 2025 | Mounjaro, Zepbound |
| Dysis Medical, INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thea Cooper Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.